Advanced Fibrosis Risk Stratification for Advanced Practice Providers
Metabollic Liver Disease Advanced Practice Providers (APPs) need actionable strategies for the identification of patients at risk for the rapid progression of metabolic dysfunction—associated liver disease (MDCLD) to help manage the increasing number of patients with metabolic dysfunction (affecting liver). Approximation of an individual's risk of experiencing liver-related morbidity and mortality through accurate and early identification of advanced fibrosis is crucial to the decision-making process to mitigate the risk of harm. The MASLD Community Network offers Advanced Practice Providers structured assessment models, non-invasive assessment tools, and instructional resources to help with the assessment of advanced fibrosis. APPs are better able to assess advanced fibrosis and help patients achieve their desired health outcomes through the implementation of risk assessment tools, and other evidence-based and patient-centered strategies available through the MASLD Community Network.
Advanced fibrosis risk assessment for advanced practice providers aids in the early identification of high-risk patients and the implementation of strategies to decrease long-term complications. APPs enhance both liver and overall metabolic health through the combination of clinically driven validated non-invasive techniques and a multidisciplinary approach. Masld Community Network offers collaborative resources and advanced practice providers the ability to practice timely, precise, and systematic fibrosis risk assessments in their clinical practice.
